NASDAQ:DNTH Dianthus Therapeutics Q3 2024 Earnings Report $80.51 0.00 (0.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$80.50 -0.01 (-0.01%) As of 06/5/2026 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Dianthus Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$0.59Beat/MissMissed by -$0.15One Year Ago EPSN/ADianthus Therapeutics Revenue ResultsActual Revenue$2.17 millionExpected Revenue$1.07 millionBeat/MissBeat by +$1.10 millionYoY Revenue GrowthN/ADianthus Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeN/AConference Call DateThursday, November 7, 2024Conference Call Time4:00PM ETUpcoming EarningsDianthus Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, August 4, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product PipelineJune 5 at 8:14 PM | insidermonkey.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of "Buy" from AnalystsJune 5 at 3:15 AM | americanbankingnews.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Simrat Randhawa Sells 26,530 Shares of Dianthus Therapeutics (NASDAQ:DNTH) StockJune 4, 2026 | americanbankingnews.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2026 | globenewswire.comDianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To WinMay 30, 2026 | seekingalpha.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?A Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowFive Below Down 12% Post Earnings—Is the Selloff Overdone?Petco Faces Tough Competition, But Momentum Is BuildingIREN's 800MW Bet Flips the AI Power SwitchBuy the Dip? Broadcom's AI Moat Is Wider Than Ever Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
